Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals announced that two abstracts featuring preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel are set for presentation at the 2021 ASCO Annual Meeting from June 4 - 8, 2021. The initial data will highlight the effects of ORIC-101, a glucocorticoid receptor antagonist, on patients with advanced solid tumors. The company plans to release data from a second trial involving enzalutamide later this year. These presentations aim to support ORIC's efforts in addressing therapeutic resistance in cancer treatments.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) showcased four preclinical studies at the 2021 AACR virtual annual meeting, focusing on its innovative oncology treatments. Key highlights include ORIC-101's ability to overcome resistance in prostate cancer, ORIC-533's potential to reverse tumor immunosuppression, ORIC-944's superior efficacy in prostate cancer models, and ORIC-114's promising results in targeting EGFR and HER2 mutations.
These findings suggest significant progress in developing therapies that may enhance treatment effectiveness against resistant cancer types.
ORIC Pharmaceuticals reported significant advancements in its clinical operations for the year ended December 31, 2020. Their leading program, ORIC-101, is undergoing Phase 1b trials with anticipated interim data readouts slated for 2021. The company aims to file three IND/CTA applications for ORIC-533, ORIC-944, and ORIC-114, enhancing their development pipeline. As of December 31, 2020, cash and investments totaled $293.6 million, projected to sustain operations into the second half of 2023. However, R&D expenses rose significantly, indicating increased investment in pipeline development.
ORIC Pharmaceuticals, a clinical stage oncology company, announced four preclinical poster presentations at the 2021 AACR virtual annual meeting scheduled for April 10-15, 2021. The data focuses on ORIC's lead program ORIC-101 and three other candidates: ORIC-533, ORIC-944, and ORIC-114, which aim to address cancer resistance mechanisms. Each candidate shows potential best-in-class differentiation, with ORIC-101 reversing GR-mediated resistance in prostate cancer models. These advancements underscore ORIC's commitment to improving cancer treatment outcomes.
ORIC Pharmaceuticals, focused on overcoming cancer resistance, will present a company overview at two upcoming conferences. Jacob Chacko, M.D., CEO, will deliver an on-demand presentation at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and a live presentation at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Webcasts of both events will be accessible on the company’s website for 90 days. ORIC’s lead product, ORIC-101, targets glucocorticoid resistance in solid tumors and is currently in Phase 1b trials.
ORIC Pharmaceuticals, a clinical stage oncology company, announced participation in two investor conferences in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day features a virtual fireside chat on February 11 at 1:00 p.m. ET, while the LifeSci Partners Precision Oncology Day will host investor meetings on February 17. A live webcast of the fireside chat will be available on their website for 90 days post-event. ORIC focuses on developing therapies addressing cancer resistance mechanisms, with notable candidates including ORIC-101, ORIC-533, ORIC-944, and ORIC-114.
ORIC Pharmaceuticals (Nasdaq: ORIC) has outlined significant developments for 2021, focusing on clinical programs and pipeline expansion. Key highlights include the ongoing enrollment for ORIC-101 trials, with initial readouts anticipated this year. The company plans to submit three IND applications for ORIC-533, ORIC-944, and ORIC-114. Financially, ORIC reported $293.6 million in cash at the end of 2020, sufficient to fund operations into the second half of 2023. Jacob Chacko, CEO, emphasized these advancements position ORIC for a dynamic year ahead.
ORIC Pharmaceuticals, a clinical stage oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT. CEO Jacob Chacko will provide an overview of the company, which is focused on overcoming therapeutic resistance in cancer treatments. Their lead candidate, ORIC-101, is currently in Phase 1b trials for metastatic prostate cancer and advanced solid tumors in combination with Xtandi and Abraxane, respectively. A live webcast of the presentation will be available on their website.
ORIC Pharmaceuticals announced the initiation of Part II expansion of the Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, combined with Abraxane for treating advanced solid tumors. This stage will enroll up to 132 patients with pancreatic ductal adenocarcinoma, ovarian cancer, triple-negative breast cancer, and others. The recommended Phase 2 dose was found to be 160 mg of ORIC-101 with 75 mg/m² of Abraxane. The trial aims to address significant unmet medical needs in these cancer types.
ORIC Pharmaceuticals announced the completion of its underwritten public offering of 5,796,000 shares, raising approximately $133.3 million. This includes the full exercise of the underwriters’ option to purchase an additional 756,000 shares, priced at $23.00 each. The offering was managed by J.P. Morgan, Citigroup, Jefferies, and Guggenheim. Funds will support ORIC's pipeline, including its lead candidate ORIC-101, aimed at combating cancer therapeutic resistance.
